Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors

Published:2022-04-19 Issue:9 Volume:62 Page:1121-1131
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharma

Author:

Koubek Emily J.¹^ORCID,Ralya Andrew T.²,Larson Thomas R.¹³^ORCID,McGovern Renee M.¹,Buhrow Sarah A.¹,Covey Joseph M.⁴,Adjei Alex A.¹⁵,Takebe Naoko⁴,Ames Matthew M.¹⁵,Goetz Matthew P.¹⁵,Reid Joel M.¹⁵

Affiliation:

1. Department of Oncology Mayo Clinic Rochester Minnesota USA

2. CATO SMS Cary North Carolina USA

3. Molecular Pharmacology and Experimental Therapeutics Graduate Program Mayo Clinic Graduate School of Biomedical Sciences Rochester Minnesota USA

4. National Cancer Institute Bethesda Maryland USA

5. Department of Pharmacology Mayo Clinic Rochester Minnesota USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2053

Reference49 articles.

1. Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

2. CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

3. Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

4. The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor α for Degradation in Breast Cancer Cells

5. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen